# name
The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis

# metadata.dc.description.abstract[].value
Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.

# metadata.dc.rights[].value
cc-by-nc-nd (c) Rodriguez-Tajes, Sergio et al., 2023

# metadata.dc.source[].value
Articles publicats en revistes (Medicina)

# metadata.dc.title[].value
The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis